ECSP088166A - COMPOSITIONS IN MICRO PARTICLES OF THE TOPOISOMERASA INHIBITOR I 7-TER-BUTOXIIMINOMETILCAMPTOTECINA - Google Patents

COMPOSITIONS IN MICRO PARTICLES OF THE TOPOISOMERASA INHIBITOR I 7-TER-BUTOXIIMINOMETILCAMPTOTECINA

Info

Publication number
ECSP088166A
ECSP088166A EC2008008166A ECSP088166A ECSP088166A EC SP088166 A ECSP088166 A EC SP088166A EC 2008008166 A EC2008008166 A EC 2008008166A EC SP088166 A ECSP088166 A EC SP088166A EC SP088166 A ECSP088166 A EC SP088166A
Authority
EC
Ecuador
Prior art keywords
inhibitor
compositions
topoisomerasa
butoxiiminometilcamptotecina
ter
Prior art date
Application number
EC2008008166A
Other languages
Spanish (es)
Inventor
Oskar Kalb
Isabel Ottinger
Wolfgang Wirth
Walter Stebler
Agnes Taillardat
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37056484&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088166(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP088166A publication Critical patent/ECSP088166A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas en micropartículas, en donde el agente activo es un inhibidor de topoisomerasa I, en particular 7-t-butoxiiminometilcamptotecina, que es útil para el tratamiento y la prevención de enfermedades proliferativas, incluyendo cáncer.The present invention relates to pharmaceutical compositions in microparticles, wherein the active agent is a topoisomerase I inhibitor, in particular 7-t-butoxyiminomethylcamptothecin, which is useful for the treatment and prevention of proliferative diseases, including cancer.

EC2008008166A 2005-08-10 2008-02-08 COMPOSITIONS IN MICRO PARTICLES OF THE TOPOISOMERASA INHIBITOR I 7-TER-BUTOXIIMINOMETILCAMPTOTECINA ECSP088166A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70713905P 2005-08-10 2005-08-10

Publications (1)

Publication Number Publication Date
ECSP088166A true ECSP088166A (en) 2008-03-26

Family

ID=37056484

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008166A ECSP088166A (en) 2005-08-10 2008-02-08 COMPOSITIONS IN MICRO PARTICLES OF THE TOPOISOMERASA INHIBITOR I 7-TER-BUTOXIIMINOMETILCAMPTOTECINA

Country Status (20)

Country Link
EP (1) EP1915132A1 (en)
JP (1) JP2009504616A (en)
KR (1) KR20080034989A (en)
CN (1) CN101287448A (en)
AR (1) AR055602A1 (en)
AU (1) AU2006277879A1 (en)
BR (1) BRPI0614757A2 (en)
CA (1) CA2618084A1 (en)
EC (1) ECSP088166A (en)
GT (1) GT200600364A (en)
IL (1) IL189076A0 (en)
MA (1) MA29735B1 (en)
MX (1) MX2008001965A (en)
NO (1) NO20081213L (en)
PE (1) PE20070232A1 (en)
RU (1) RU2008108885A (en)
TN (1) TNSN08062A1 (en)
TW (1) TW200800195A (en)
WO (1) WO2007017514A1 (en)
ZA (1) ZA200800726B (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
IT1306129B1 (en) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti ESTERS OF L-CARNITINE OR ALCANOYL L-CARNITINE USABLE CATIONIC COMELIPIDS FOR INTRACELLULAR PLACING OF COMPOUNDS
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
GT200500310A (en) * 2004-11-19 2006-06-19 ORGANIC COMPOUNDS

Also Published As

Publication number Publication date
AU2006277879A1 (en) 2007-02-15
ZA200800726B (en) 2009-08-26
JP2009504616A (en) 2009-02-05
EP1915132A1 (en) 2008-04-30
CA2618084A1 (en) 2007-02-15
PE20070232A1 (en) 2007-04-09
AR055602A1 (en) 2007-08-29
IL189076A0 (en) 2008-08-07
GT200600364A (en) 2007-03-19
CN101287448A (en) 2008-10-15
MX2008001965A (en) 2008-03-26
NO20081213L (en) 2008-05-13
BRPI0614757A2 (en) 2011-04-12
MA29735B1 (en) 2008-09-01
WO2007017514A1 (en) 2007-02-15
RU2008108885A (en) 2009-09-20
TW200800195A (en) 2008-01-01
KR20080034989A (en) 2008-04-22
TNSN08062A1 (en) 2009-07-14

Similar Documents

Publication Publication Date Title
BRPI0809164B8 (en) COMPOSITION FOR TOPICAL ADMINISTRATION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOSITION
PH12017501306A1 (en) Inhibitors of histone demethylases
DOP2007000053A (en) TETRAHYDROPIRIDOTIENOPIRIMIDINA COMPOUNDS AND METHODS FOR USE
IN2012DN02018A (en)
CR20140108A (en) CYCLOPROPANOAMINE COMPOUND
PA8770101A1 (en) AMIDAS OF 4-ARIL-1,4-DIHIDRO-1, 6-NAFTIRIDINE SUBSTITUTED AND ITS USE
GT200600194A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING IMATINIB AND A PROLONGED RELEASE COMPONENT
UY32456A (en) FAMOUS COMPOSITION, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, METHODS OF TREATMENT
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CL2008001633A1 (en) Compounds derived from pyrrolidin-3-carboxamide; pharmaceutical composition; and use as erk inhibitors for the treatment of cancer.
BR112012009376B8 (en) solid pharmaceutical composition comprising a sglt-2 inhibitor and its pharmaceutical dosage form
UY30905A1 (en) COMPOSITIONS TO IMPROVE GASTROINTESTINAL ABSORPTION OF NUTRIENTS AND PHARMACOS
GT200800250A (en) ARILIMIDAZOLONAS AND ARILTRIAZOLONAS REPLACED AS INHIBITORS OF VASOPRESINE RECEPTORS
HN2012000023A (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
CL2014001838A1 (en) Compounds derived from fluormethyl-5,6-dihydro-4h- [1,3] oxazin-2-ylamine, as bace1 inhibitors; its process of obtaining; pharmaceutical composition that contains them; and its use for the therapeutic and / or prophylactic treatment of Alzheimer's disease, amyotrophic lateral sclerosis, cancer, cardiovascular diseases and gastrointestinal diseases, among others.
CR11684A (en) REPLACED DIHYDROPIRAZOLONES OF HIF-PROPIL-4- AS HYDROXYLASE INHIBITORS
CR10975A (en) FORMULATIONS FOR CANCER TREATMENT
CR9427A (en) THERAPEUTIC COMBINATION IN CASES OF BENIGN PROSTATIC HYPERPLASIA
HN2010002518A (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A STRONTIUM SALT, VITAMIN D AND A CYCLODEXTRINE
DOP2010000302A (en) ANTAGONISTS OF THE HEDGEHOG TRAJECTORY OF DISTTITUTED FTALAZINA
CU24349B1 (en) COMPOSITIONS INCLUDING 2,3-DIHYDROIMIDAZO [1,2-C] SUBSTITUTED KINAZOLINS USEFUL FOR TREATMENT OF CANCER
BRPI0518448A2 (en) pharmaceutical compositions comprising a camptothecin derivative
ECSP088745A (en) SUBSTITUTED DERIVATIVES OF CHROMANOL AND ITS USE
CL2007003356A1 (en) COMPOUNDS DERIVED FROM BENZOPIRAZOLES; PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS AND ANOTHER ACTIVE AGENT; AND ITS USE FOR THE TREATMENT OF ASTHMA, INFLAMMATION, AMONG OTHER DISEASES.
BRPI1015539A2 (en) burn treatment compositions and methods